140 related articles for article (PubMed ID: 27830363)
1. Dysregulated expression of homebox gene HOXA13 is correlated with the poor prognosis in bladder cancer.
Hu H; Chen Y; Cheng S; Li G; Zhang Z
Wien Klin Wochenschr; 2017 Jun; 129(11-12):391-397. PubMed ID: 27830363
[TBL] [Abstract][Full Text] [Related]
2. Expression of long noncoding RNA lncRNA-n336928 is correlated with tumor stage and grade and overall survival in bladder cancer.
Chen T; Xie W; Xie L; Sun Y; Zhang Y; Shen Z; Sha N; Xu H; Wu Z; Hu H; Wu C
Biochem Biophys Res Commun; 2015 Dec; 468(4):666-70. PubMed ID: 26551459
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation that up-expression of HOXA13 is a novel independent prognostic marker of a worse outcome in gastric cancer based on immunohistochemistry.
Han Y; Tu WW; Wen YG; Li DP; Qiu GQ; Tang HM; Peng ZH; Zhou CZ
Med Oncol; 2013; 30(2):564. PubMed ID: 23592225
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of HOXA13 as a potential marker for diagnosis and poor prognosis of hepatocellular carcinoma.
Pan TT; Jia WD; Yao QY; Sun QK; Ren WH; Huang M; Ma J; Li JS; Ma JL; Yu JH; Ge YS; Liu WB; Zhang CH; Xu GL
Tohoku J Exp Med; 2014 Nov; 234(3):209-19. PubMed ID: 25341685
[TBL] [Abstract][Full Text] [Related]
5. Homeobox-A13 acts as a functional prognostic and diagnostic biomarker via regulating P53 and Wnt signaling pathways in lung cancer.
Wang Y; He B; Dong Y; He GJ; Qi XW; Li Y; Yang YF; Rao Y; Cen ZS; Han F; Ding J; Li JJ
Cancer Biomark; 2021; 31(3):239-254. PubMed ID: 33896818
[TBL] [Abstract][Full Text] [Related]
6. Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer.
Lin YL; Wang YL; Fu XL; Li WP; Wang YH; Ma JG
Oncotarget; 2016 May; 7(19):28384-92. PubMed ID: 27070091
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic and prognostic significance of p21 (Cip1/Waf1) expression in bladder cancer.
Tang K; Wang C; Chen Z; Xu H; Ye Z
Int J Clin Exp Pathol; 2015; 8(5):4999-5007. PubMed ID: 26191193
[TBL] [Abstract][Full Text] [Related]
8. HOXA13 is associated with unfavorable survival and acts as a novel oncogene in prostate carcinoma.
Dong Y; Cai Y; Liu B; Jiao X; Li ZT; Guo DY; Li XW; Wang YJ; Yang DK
Future Oncol; 2017 Jul; 13(17):1505-1516. PubMed ID: 28766961
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-148a represents an independent prognostic marker in bladder cancer.
Ma L; Xu Z; Xu C; Jiang X
Tumour Biol; 2016 Jun; 37(6):7915-20. PubMed ID: 26700670
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of long non‑coding RNA n346372 in bladder cancer tissues is associated with a poor prognosis.
Liu A; Zhang Z; Xu W; Qin S; Hua M; Zeng S; Xu C
Mol Med Rep; 2018 Dec; 18(6):5437-5444. PubMed ID: 30365104
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
Lin YL; Wang YL; Ma JG; Li WP
J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
[TBL] [Abstract][Full Text] [Related]
12. An insight into the diagnostic and prognostic value of HOX A13's expression in non-muscle invasive bladder cancer.
Setti Boubaker N; Gurtner A; Trabelsi N; Manni I; Blel A; Saadi A; Chakroun M; Naimi Z; Zaghbib S; Ksontini M; Meddeb K; Rammeh S; Ayed H; Chebil M; Piaggio G; Ouerhani S
J Clin Lab Anal; 2022 Sep; 36(9):e24606. PubMed ID: 35853090
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of Aurora-A expression in human bladder cancer.
Lei Y; Yan S; Ming-De L; Na L; Rui-Fa H
Acta Histochem; 2011 Sep; 113(5):514-8. PubMed ID: 20598352
[TBL] [Abstract][Full Text] [Related]
14. P3H4 is correlated with clinicopathological features and prognosis in bladder cancer.
Li W; Ye L; Chen Y; Chen P
World J Surg Oncol; 2018 Oct; 16(1):206. PubMed ID: 30322400
[TBL] [Abstract][Full Text] [Related]
15. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.
Zhu X; Qiao Y; Liu W; Wang W; Shen H; Lu Y; Hao G; Zheng J; Tian Y
Tumour Biol; 2016 Apr; 37(4):4569-77. PubMed ID: 26503215
[TBL] [Abstract][Full Text] [Related]
16. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.
Patry G; Hovington H; Larue H; Harel F; Fradet Y; Lacombe L
Int J Cancer; 2008 Apr; 122(7):1592-7. PubMed ID: 18058798
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of ESCO1 is correlated with poor patient survival and its role in human bladder cancer.
Zhang S; Li J; Zhou G; Mu D; Yan J; Xing J; Yao Z; Sheng H; Li D; Lv C; Sun B; Hong Q; Guo H
Tumour Biol; 2016 Apr; 37(4):5165-70. PubMed ID: 26547586
[TBL] [Abstract][Full Text] [Related]
18. Loss of DUSP2 predicts a poor prognosis in patients with bladder cancer.
Yin H; He W; Li Y; Xu N; Zhu X; Lin Y; Gou X
Hum Pathol; 2019 Mar; 85():152-161. PubMed ID: 30458195
[TBL] [Abstract][Full Text] [Related]
19. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer.
Theodorescu D; Sapinoso LM; Conaway MR; Oxford G; Hampton GM; Frierson HF
Clin Cancer Res; 2004 Jun; 10(11):3800-6. PubMed ID: 15173088
[TBL] [Abstract][Full Text] [Related]
20. Expression of beclin 1 in bladder cancer and its clinical significance.
Liu GH; Zhong Q; Ye YL; Wang HB; Hu LJ; Qin ZK; Zeng MS; Zeng BH
Int J Biol Markers; 2013 Apr; 28(1):56-62. PubMed ID: 23125008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
